Preemptive HCT remains an attractive option for patients with HHM variants associated with deleterious systemic clinical phenotypes (GATA2 deficiency, for example), but non-relapse mortality remains a serious obstacle towards more uniform deployment of potentially curative strategies to replace deleterious stem cell populations. Here, GATA2 is linked to hyperinsulinemic hypoglycemia, familial, 4.